Dec. 30 at 3:25 PM
EUDA Health Holdings Limited said it has launched a national stem cell extraction, cryogenic storage, and clinical delivery platform in China, marking a major step in the company’s regenerative medicine strategy. The Singapore-based non-invasive healthcare provider has partnered with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital to expand its nationwide clinical and logistics network.
The platform integrates cell extraction, processing, long-term cryogenic storage, logistics, and clinical application, and is built around a centralized processing model with decentralized patient access. Shenzhen Inno Immune will serve as the primary cell-processing hub in southern China with capacity for about 50,000 patient cell units, while Wuhan Kaien Hospital will act as the flagship clinical center in central China with planned capacity of up to 200,000 patient cell units.
$EUDA